Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

apolizumab

A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	1D10 anti-lymphoma antibody 1D1O anti-lymphoma antibody MAbHu1D10 monoclonal antibody 1D10 monoclonal antibody Hu1D10
US brand name:	Remitogen
Abbreviation:	MOAB 1D10 MoAb Hu1D10
IND number:	8308 9968
NSC code:	710066

apolizumab

Search NCI's Drug Dictionary